|
Trial Name/Sponsor |
Patient Diagnosis |
Description of Trial |
| ACCLAIM Lp(a) Eli Lilly and Company |
Cardiovascular Disease/Lipoprotein(a) | A phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) who have established atherosclerotic cardiovascular disease or are at risk for a first cardiovascular event – ACCLAIM-Lp(a). |
| AZURE-OUTCOMES AstraZeneca |
Atherosclerotic Cardiovascular Disease | A phase III, randomized, double-blind, placebo-controlled, parallel-group study to assess the effect of AZD0780 on major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD) or at high risk for a first ASCVD event” in adults. |
COMET-HF |
Heart Failure | A multi-center, double-blind, randomized, placebo-controlled trial to assess efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. |
| FINALITY-HF CPC Clinical Research |
Heart Failure | A randomized, double-blind, placebo-controlled pragmatic study to evaluate finerenone on clinical efficacy and safety in patients with heart failure and reduced ejection fraction who are intolerant of or no teligible for treatment with sterioidal mineralocorticoid receptor antagnoists. |
| HERMES Novo Nordisk Canada Inc. |
Heart Failure | Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. |
| HORIZON Novartis |
Cardiovascular Disease | A randomized double-blind, placebo-controlled study, multicenter trial assessing the impact of lipoprotein (a) lowring with pelacarsen (TQJ230) on major cardiovascular events in pateints with established cardiovascular disease. |
| HORIZON OLE Novartis |
Cardiovascular Disease | A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial. |
| OCEAN(a) Amgen Canada Inc. |
Cardiovascular Disease | A Double blind, Randomized, Placebo controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a). |
| OCEAN(a) PreEvent Amgen Canada Inc. |
Cardiovascular Disease | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a). |
MOVE Lp(a) Eli Lilly and Company |
Cardiovascular Disease/Lipoprotein Lp(a) | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event – MOVE-Lp(a). |
ON-X On-X Life Technologies, Inc. |
Aortic Valve Prosthetic Heart Valve | On-X® aortic valve prosthetic heart valve low dose warfarin post approval clinical registry study. |
| SAVE BC UBC |
Province-wide Biobank | Study to Avoid cardioVascular Events in British Columbia. |
SMART |
Aortic Valve Replacement | Small Annuli Randomized to Evolut or SAPIEN Trial. |
| SYNCHRONIZE_CVOT Boehringer-Ingelheim (Canada) Ltd. | Cardiovascular Disease/Obesity | A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity. |
VICTORION-2 PREVENT |
Cardiovascular Disease | A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease. |
©Victoria Heart Institute Foundation
"Yesterday's research is tomorrow's best practice... Today's research leads to tomorrow's breakthroughs."